Value of early circulating tumor cells dynamics to estimate docetaxel benefit in metastatic castration-resistant prostate cancer (Mcrpc) patients

Rebeca Lozano, David Lorente, Isabel M. Aragon, Nuria Romero-Laorden, Paz Nombela, Joaquim Mateo, Alison H.M. Reid, Ylenia Cendón, Diletta Bianchini, Casilda Llacer, Shahneen K. Sandhu, Adam Sharp, Pasquale Rescigno, Teresa Garcés, Maria I. Pacheco, Penelope Flohr, Christophe Massard, Pedro P. López-Casas, Elena Castro, Johann S. de BonoDavid Olmos

    Research output: Contribution to journalArticlepeer-review

    12 Citations (Scopus)

    Abstract

    Circulating tumor cell (CTC) enumeration and changes following treatment have been demonstrated to be superior to PSA response in determining mCRPC outcome in patients receiving AR signaling inhibitors but not taxanes. We carried out a pooled analysis of two prospective studies in mCRPC patients treated with docetaxel. CTCs were measured at baseline and 3–6 weeks post treatment initiation. Cox regression models were constructed to compare 6-month radiographical progression-free survival (rPFS), CTCs and PSA changes predicting outcome. Among the subjects, 80 and 52 patients had evaluable baseline and post-treatment CTC counts, respectively. A significant association of higher baseline CTC count with worse overall survival (OS), PFS and time to PSA progression (TTPP) was observed. While CTC response at 3–6 weeks (CTC conversion (from ≥5 to <5 CTCs), CTC30 (≥30% decline in CTC) or CTC0 (decline to 0 CTC)) and 6-month rPFS were significantly associated with OS (all p < 0.005), the association was not significant for PSA30 or PSA50.

    Original languageEnglish
    Article number2334
    JournalCancers
    Volume13
    Issue number10
    DOIs
    Publication statusPublished - 2 May 2021

    Keywords

    • Biomarkers
    • Circulating tumor cells
    • Docetaxel
    • Metastatic castration-resistant prostate cancer
    • PSA

    Cite this